Ayala Pharmaceuticals (STU:FAD) Cash Flow for Dividends : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Ayala Pharmaceuticals Cash Flow for Dividends?

Ayala Pharmaceuticals's cash flow for dividends for the three months ended in Dec. 2023 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Ayala Pharmaceuticals Cash Flow for Dividends Historical Data

The historical data trend for Ayala Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ayala Pharmaceuticals Cash Flow for Dividends Chart

Ayala Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow for Dividends

Get a 7-Day Free Trial

Ayala Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Cash Flow for Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Ayala Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Ayala Pharmaceuticals Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Ayala Pharmaceuticals's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Ayala Pharmaceuticals (STU:FAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (STU:FAD) » Definitions » Cash Flow for Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oppenheimer 4, Rehovot, ISR, 7670104

Website

https://www.ayalapharma.com

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma-secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma-secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell-specific leukemia.